Endo International PLC (ENDPQ)
|Net Income (ttm)||n/a|
|Day's Range||0.120 - 0.134|
|52-Week Range||0.092 - 0.230|
|Price Target||1.02 (+691.3%)|
|Earnings Date||Nov 7, 2022|
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PE... [Read more...]
Financial PerformanceFinancial Statements
Endo (ENDP) finally files for bankruptcy after negotiations with its debtholders as litigation claims continue to weigh on the business.
The generic drugmaker faces thousands of lawsuits related to its alleged role in the opioid crisis.
Oxycodone maker Endo International files for bankruptcy and will put itself up for sale.
Endo Enters Into Restructuring Support Agreement with Senior Secured Debtholders to Strengthen Financial Position and...
Sale Transaction Would Result in a Substantial Reduction of Debt and Contemplates Purchaser-Established Voluntary Trusts Funded with $550 Million to Benefit Opioid Claimants Patients and Customers Will ...
It hasn't been a good run for Endo International (NASDAQ: ENDP ), and Tuesday isn't making it any better. Shares of ENDP stock are down more than 40% today and almost 60% from last week's high.
Endo (ENDP) delivered earnings and revenue surprises of 118.75% and 9.01%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
SK Biopharmaceuticals is eligible to receive milestones for future approval and commercialization in Canada and Israel PANGYO, South Korea , Aug. 9, 2022 /PRNewswire/ -- SK Biopharmaceuticals, Co., Ltd....
DUBLIN , Aug. 9, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today reported financial results for the second-quarter ended June 30, 2022. SECOND-QUARTER FINANCIAL PERFORMANCE (in thousand...
Buxton Helmsley Issues Letter to Endo International Plc. Directors, Relating to Financial Disclosures
NEW YORK--(BUSINESS WIRE)--The Buxton Helmsley Group, Inc. (together with certain of its affiliates and clients, “BHG” or “we”), the New York City-based investment advisor to clients with financial inte...
Endo's (ENDP) subsidiary, Endo Ventures, signs agreement with Quoin Pharmaceuticals for developing/commercializing the latter's pipeline candidate, QRX003, for treating Netherton syndrome in Canada.
Endo Announces Agreement for Paladin Labs to Develop, Commercialize and Supply Quoin Pharmaceuticals' QRX003 in Canada
The product is under investigation for the treatment of Netherton syndrome, a rare disease DUBLIN , July 15, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that its subsidiar...
After a week of roller-coaster price action, ENDP stock is on the upswing even after Endo International posts disappointing clinical results. The post Why Is Endo International (ENDP) Stock Up Today?
Endo (ENDP) mid-stage study of collagenase clostridium histolyticum (or CCH) for treating frozen shoulder disappoints.
DUBLIN , July 1, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that a federal jury in Chicago, Illinois, has returned a verdict in favor of the Company's subsidiaries Endo P...
Endo International PLC (NASDAQ: ENDP) shares are trading lower by 16.86% to $0.39 after the company provided top-line results from its Phase 2 study of CCH in patients with adhesive capsulitis of the sh...
Endo International plc (NASDAQ: ENDP) has announced topline results from its Phase 2 study of collagenase clostridium histolyticum (CCH) in participants with adhesive capsulitis (AC) of the shoulder (fr...
Endo Provides Top-Line Results from Phase 2 Study of Collagenase Clostridium Histolyticum (CCH) in Participants with ...
DUBLIN , July 1, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced top-line results from its Phase 2 study of Collagenase Clostridium Histolyticum (or "CCH") in participants wit...
Here's what investors may want to know about today's 20% downside move in ENDO stock, a day after this stock rocketed 90% higher. The post Endo International (ENDP) Stock Plunges 20% After Missing Inter...
Endo International (ENDO) tanks 26%, cooling off after its massive stock price surge on Tuesday, post the Supreme Court's decision to overturn Roe v. Wade.
Endo International has been surging all day but it isn't just Plan B that has kept it rising. Here's why ENDP stock is a name to watch.
Endo (ENDP) collaborates with Taiwan Liposome to commercialize TLC599, an extended and controlled release liposomal formulated dexamethasone for chronic knee osteoarthritis (OA) pain.
Endo Executes Agreement With TLC to Commercialize Phase 3 Orthopedic Product for the Treatment of Osteoarthritis Knee...
DUBLIN , June 13, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited (EVL) has executed an agreement with Taiwan Liposome Company, Ltd. ...
Endo (ENDP) plunges on reports of negotiations with its lenders and senior bondholders about a possible restructuring of more than $8 billion of debt.